Citigroup Maintains Neutral on Health Catalyst, Lowers Price Target to $2
Citigroup analyst Daniel Grosslight maintains Health Catalyst (NASDAQ: HCAT ) with a Neutral and lowers the price target from $2.5 to $2.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.